Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
Related Questions
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How do you interpret a negative ANCA and a low positive PR3?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
Do you start bisphosphonates after tapering off menopausal hormone therapy to prevent the rapid decline of bone mineral density?
How do you approach worsening memory loss in patients with GCA?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
